Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ESPR 
Esperion Therapeutics Inc (ESPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ESPR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.79
1 Year Target Price $5.79
| 2 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.57% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 245.77M USD | Price to earnings Ratio - | 1Y Target Price 5.79 |
Price to earnings Ratio - | 1Y Target Price 5.79 | ||
Volume (30-day avg) 7 | Beta 0.65 | 52 Weeks Range 0.69 - 3.94 | Updated Date 07/12/2025 |
52 Weeks Range 0.69 - 3.94 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -59.03% | Operating Margin (TTM) -34% |
Management Effectiveness
Return on Assets (TTM) -7.17% | Return on Equity (TTM) -260.79% |
Valuation
Trailing PE - | Forward PE 1.34 | Enterprise Value 419008359 | Price to Sales(TTM) 0.95 |
Enterprise Value 419008359 | Price to Sales(TTM) 0.95 | ||
Enterprise Value to Revenue 1.61 | Enterprise Value to EBITDA 48.73 | Shares Outstanding 198199008 | Shares Floating 196037106 |
Shares Outstanding 198199008 | Shares Floating 196037106 | ||
Percent Insiders 0.57 | Percent Institutions 59.27 |
Upturn AI SWOT
Esperion Therapeutics Inc
Company Overview
History and Background
Esperion Therapeutics, Inc. was founded in 1998, focusing initially on developing therapies for cardiovascular diseases. After an initial public offering in 2000, the company was acquired by Pfizer in 2004. Esperion was then relaunched in 2008 with a new focus on developing and commercializing therapies for lowering LDL-cholesterol.
Core Business Areas
- Cardiovascular Disease Therapeutics: Development and commercialization of oral, once-daily therapies to lower LDL-cholesterol (bad cholesterol) for patients with elevated LDL-C at risk for cardiovascular disease.
Leadership and Structure
Sheldon Koenig is the President and CEO. The organizational structure is typical of a biotechnology company, with departments focused on research and development, clinical trials, commercial operations, finance, and administration.
Top Products and Market Share
Key Offerings
- NEXLETOL (bempedoic acid): An oral, once-daily non-statin LDL-cholesterol lowering medicine. Market share is growing but still relatively small compared to statins and other lipid-lowering medications. Competitors include statins (atorvastatin, simvastatin), ezetimibe (Zetia), PCSK9 inhibitors (Repatha, Praluent), and generic versions of these drugs. Estimated 2023 revenue is around $72 million.
- NEXLIZET (bempedoic acid and ezetimibe): A fixed-dose combination of bempedoic acid and ezetimibe, also an oral, once-daily non-statin LDL-cholesterol lowering medicine. Competitors are similar to NEXLETOL. Estimated 2023 revenue is around $18 million.
Market Dynamics
Industry Overview
The cardiovascular disease therapeutics market is large and competitive, driven by the high prevalence of hypercholesterolemia and the need for effective LDL-C lowering therapies. The market includes statins, non-statin medications like ezetimibe and PCSK9 inhibitors, and emerging therapies.
Positioning
Esperion is positioned as a non-statin option for LDL-C lowering, targeting patients who cannot tolerate statins or need additional LDL-C lowering beyond statins. Their competitive advantage lies in their oral, once-daily administration and novel mechanism of action.
Total Addressable Market (TAM)
The global market for LDL-C lowering drugs is estimated at tens of billions of dollars annually. Esperion is focused on capturing a portion of the non-statin market. The TAM for this is roughly $5 Billion, with Esperion aiming to address the needs of patients who do not respond well to traditional statin-based therapies.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for LDL-C lowering
- Oral, once-daily administration
- Approved therapies in NEXLETOL and NEXLIZET
- Focused on a specific patient population
Weaknesses
- Limited market share compared to statins
- Relatively high drug prices
- Dependence on two main products
- Requires significant marketing and sales efforts to compete with established therapies
Opportunities
- Expanding indications for NEXLETOL and NEXLIZET
- Partnering with larger pharmaceutical companies
- Increasing awareness of non-statin options
- Further clinical trial data demonstrating cardiovascular outcomes benefits
Threats
- Competition from generic statins and other LDL-C lowering therapies
- Pricing pressures from payers
- Regulatory changes
- Failure to achieve significant market penetration
Competitors and Market Share
Key Competitors
- PFE
- MRK
- AMGN
- REGN
Competitive Landscape
Esperion faces intense competition from established pharmaceutical companies with established LDL-C lowering therapies. Esperionu2019s advantages are its oral administration and novel mechanism, but it struggles with marketing reach and pricing pressures.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow, with challenges in achieving significant market penetration.
Future Projections: Future growth is dependent on the successful commercialization of NEXLETOL and NEXLIZET and potential label expansions. Analyst estimates vary widely.
Recent Initiatives: Focus on improving sales force effectiveness, expanding marketing efforts, and pursuing clinical trials to demonstrate cardiovascular outcomes benefits. Announced restructuring and focusing on commercial excellence.
Summary
Esperion Therapeutics is a high-risk, high-reward biotechnology company focused on LDL-C lowering therapies. Its novel drugs offer an alternative to statins, but face strong competition. The company struggles to generate profitability and requires ongoing financing to operate. Future success depends on its ability to capture a significant share of the non-statin market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Materials
- Analyst Reports
- Industry News and Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market information are subject to change. Market share data is estimated and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Esperion Therapeutics Inc
Exchange NASDAQ | Headquaters Ann Arbor, MI, United States | ||
IPO Launch date 2013-06-26 | President, CEO & Director Mr. Sheldon L. Koenig | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 304 | Website https://www.esperion.com |
Full time employees 304 | Website https://www.esperion.com | ||
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.